Search - tctmd.com

Displaying 21 - 40 of 118

Sort: Relevancy | Date

Presentation TCT 2025

Predictors of a Positive Treadmill Stress Test in Patients with Asymptomatic Severe Aortic Stenosis: Insights from the EARLY TAVR Treadmill Registry

Presenter: Philippe Genereux

October 25, 2025

Presentation TCT 2025

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Women with Severe Aortic Stenosis: The RHEIA Trial

Presenter: Philippe Pibarot

October 25, 2025

Presentation TCT 2025

Thirty-Day and One-Year Outcomes of the Navitor TAVR System in Patients with Low or Intermediate Risk

Presenter: Stephen Grant Worthley

October 25, 2025

Presentation TCT 2025

Valve Performance of Self-Expanding vs. Balloon-Expandable TAVR in Patients with a Small Aortic Annulus: Five-Year Results From the OCEAN-TAVI Registry

Presenter: Fumiaki Yashima

October 25, 2025

Presentation TCT 2025

Early Outcomes of Redo-TAVI With SAPIEN Platform in a Real-World Prospective Cohort: The ReTAVI Registry

Presenter: Giuseppe Tarantini

October 25, 2025

Presentation Interventional Complications 2025

I Am in Trouble (Hospital, Partners and/or Medical Staff)

Presenter: Cynthia Rutzick

July 11, 2025

Presentation NY Valves 2025

SAVR vs. TAVR Strategy Trials (PARTNER 3 and RHEIA)

Presenter: Didier Tchetche

June 27, 2025

Presentation NY Valves 2025

30-Day Outcomes of the Lux-Plus TTVR System in Large Tricuspid Annuli in the TRINITY Trial

Presenter: Thomas Elie Modine

June 25, 2025

Presentation NY Valves 2025

SIEGEL TAVR: FIH 1 year & US Early Feasibility 30 Day Results

Presenter: Pradeep K. Yadav

June 25, 2025

Presentation NY Valves 2025

PRO – SURGERY: 3 Reasons Why Surgery Is the Best Option for This Patient

Presenter: Christine J. Chung

June 25, 2025

Presentation NY Valves 2025

PRO – TAVR: 3 Reasons Why TAVR Is the Best Option for This Patient

Presenter: Isaac George

June 25, 2025

Presentation TCT 2024

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Presenter: Didier Tchetche

October 29, 2024

Presentation NY Valves 2024

Partner Valves: Role of a Prospective Device Selection Strategy Using Acurate and SAPIEN 3 as Complementary Devices in Transcatheter Aortic Valve Replacement

Presenter: Jonathan Michel

June 07, 2024

Presentation TCT 2023

Position 3: Initial TAVR

Presenter: Mathew Williams

October 25, 2023

Presentation TCT 2023

Importance of Patient Reported Outcomes

Presenter: David Cohen

October 24, 2023

Presentation TCT 2023

An Echo Deep Dive of the PARTNER 5-Year Study

Presenter: Philippe Pibarot

October 24, 2023

Presentation TCT 2023

Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY

Presenter: Raj Makkar

October 24, 2023

Presentation TCT 2023

Perspectives on Mortality in the PARNTER 5-Year Study

Presenter: Vinod Thourani

October 24, 2023

Presentation TCT 2023

Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial

Presenter: Rebecca Hahn

October 24, 2023

Advertisement

Predictors of a Positive Treadmill Stress Test in Patients with Asymptomatic Severe Aortic Stenosis: Insights from the EARLY TAVR Treadmill Registry

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Women with Severe Aortic Stenosis: The RHEIA Trial

Thirty-Day and One-Year Outcomes of the Navitor TAVR System in Patients with Low or Intermediate Risk

Valve Performance of Self-Expanding vs. Balloon-Expandable TAVR in Patients with a Small Aortic Annulus: Five-Year Results From the OCEAN-TAVI Registry

Early Outcomes of Redo-TAVI With SAPIEN Platform in a Real-World Prospective Cohort: The ReTAVI Registry

I Am in Trouble (Hospital, Partners and/or Medical Staff)

SAVR vs. TAVR Strategy Trials (PARTNER 3 and RHEIA)

30-Day Outcomes of the Lux-Plus TTVR System in Large Tricuspid Annuli in the TRINITY Trial

SIEGEL TAVR: FIH 1 year & US Early Feasibility 30 Day Results

PRO – SURGERY: 3 Reasons Why Surgery Is the Best Option for This Patient

PRO – TAVR: 3 Reasons Why TAVR Is the Best Option for This Patient

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Partner Valves: Role of a Prospective Device Selection Strategy Using Acurate and SAPIEN 3 as Complementary Devices in Transcatheter Aortic Valve Replacement

Position 3: Initial TAVR

Importance of Patient Reported Outcomes

An Echo Deep Dive of the PARTNER 5-Year Study

Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY

Perspectives on Mortality in the PARNTER 5-Year Study

Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content